An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals /CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying the new price can be cost effective to treat sickle cell disease.
The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.
AbbVie Inc and partner Johnson & Johnson intend to voluntarily withdraw the accelerated approvals of their Imbruvica drug in the U.S. for patients with certain types of blood cancer, the companies said on Thursday.
Slovenia said on Tuesday it may ban Johnson & Johnson's Janssen COVID-19 vaccine except when people request it, after concluding a young woman's death was linked to the shot.